ALK and non-small cell lung carcinoma: Ceritinib is a second-generation ALK inhibitor, and a dose of 450 mg daily administered with food has a more favorable safety profile in both treatment and pretreated patients with ALK+ metastatic NSCLC.[16] Wu et al[2] reported that overall intracranial response rate and intracranial disease control rate (DCR) in patients with brain metastases treated with ceritinib were 39.1% and 82.6%, respectively, and the mean PFS was 5.7 months.